SPY380.36-1.97 -0.52%
DIA309.45-4.53 -1.44%
IXIC13,192.35+72.96 0.56%

Erytech Phase 3 Trial of Eryaspase in Pancreatic Cancer to Continue to Final Analysis Following Committee Review

· 02/07/2021 22:56

03:44 AM EST, 02/08/2021 (MT Newswires) -- Erytech Pharma S.A. (ERYP) said Monday that an independent data monitoring committee has recommended the continuation without modification of the company's phase 3 trial of eryaspase in second-line pancreatic cancer.

The recommendation follows an interim superiority analysis by the committee with no safety issues identified.

The trial is fully enrolled and the company expects the final efficacy analysis to begin in Q4.

Price: 11.20, Change: -0.72, Percent Change: -6.04